Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222147 | 0.91 | ALB (0.47) | ALBPSMB5PSMB8MAOBNR4A1 | |
| SCHEMBL13964510 | 0.78 | PSMB5 (0.34) | PSMB5PSMB8MAPTCREBBPCES2 | |
| SCHEMBL29853275 | 0.71 | MAOB (0.49) | MAOBNR4A1NR4A2NR4A3GPR35 | |
| SCHEMBL2729243 | 0.71 | MAOB (0.49) | MAOBNR4A1NR4A2NR4A3GPR35 | |
| SCHEMBL4007022 | 0.71 | TSHR (0.48) | PSMB5PSMB8MAOBNR4A1NR4A2 | |
| SCHEMBL23360189 | 0.71 | MCL1 (0.51) | PSMB5PSMB8MAOBNR4A1NR4A2 | |
| SCHEMBL31491647 | 0.71 | ALB (0.47) | ALBPSMB5PSMB8MAOBNR4A1 | |
| SCHEMBL29862590 | 0.68 | CES2 (0.37) | ALBMAOBGPR35MAPTCREBBP | |
| SCHEMBL23360431 | 0.68 | CES2 (0.37) | ALBMAOBGPR35MAPTCREBBP | |
| SCHEMBL7948373 | 0.68 | ALDH1A1 (0.51) | PSMB5PSMB8MAOBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1463728-A4 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1463728-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | disclosed |
| WO-2003053354-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ALB 4689/4885PSMB5 1146/4885PSMB8 975/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ALB 4689/4885PSMB5 1146/4885PSMB8 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.